Below is a list of clinical trials currently offered at the Cancer Institute of Florida Hospital Memorial Medical Center.
For any questions or to learn if you qualify for a trial, please contact our clinical trial research coordinators at (386) 231-4023 or (386) 231-4026.
Breast Cancer Studies
S1007: Clinical Trial of Standard Adjuvant Endocrine Therapy +/- Chemotherapy in Patients with 1-3 Positive Nodes, Hormone Receptor-Positive and HER2-Negative Breast Cancer with Recurrence Score (RS) of 25 or Less.
S1207: “Phase III, Randomized Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients with High Risk, Hormone Receptor-Positive and HER2/neu Negative Breast Cancer.
Lung Cancer Studies
S0819 Phase III Randomized Study of Carboplatin/Paclitaxel or Carboplatin/Paclitaxel/Bevacizumab With or Without Concurrent Cetuximab in Patients With Stage IV or Recurrent Non-Small Cell Lung Cancer (NSCLC) (temp. closed)
Castle Bioscience: Development and Validation of a Gene Expression Assay to Predict the Risk of Metastatic Disease in Malignant Cutaneous Melanoma
Amgen 20110266: A Phase 2, Multicenter, Randomized, Open-label Trial Assessing the Efficacy and Safety of Talimogene Laherparepvec Neoadjuvant Treatment Plus Surgery Versus Surgery Alone for Resectable, Stage IIIB to IVM1a Melanoma
Amgen 20120166: A Phase 3b, Multicenter, Open-label, Single-arm, Expanded Access Protocol of Talimogene Laherparepvec for the Treatment of Subjects With Unresected,Stage lllB to IVM1c Melanoma (coming soon)
Amgen 20120139: "A Registry Study to Evaluate the Survival and Long-Term Safety of Subjects with Melanoma Who Previously Received Talimogene Laherparepvec." (coming soon)
A221101 “A Phase III Randomized, Double-Blind Placebo Controlled Study of Armodfinil (Nuvigil) To Reduce Cancer-Related Fatigue in Patients with Glioblastoma
Nausea Prevention Studies
A221301, Olanzapine for the Prevention of Chemotherapy Induced Nausea and Vomiting (CINV) in Patients Receiving Highly Emetogenic Chemotherapy (HEC)